Dimensional Fund Advisors’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.43M Sell
18,595
-4,075
-18% -$886K ﹤0.01% 2594
2026
Q2
$5.55M Buy
22,670
+7,510
+50% +$1.63M ﹤0.01% 2509
2026
Q1
$2.56M Buy
15,160
+2,729
+22% +$471K ﹤0.01% 2652
2025
Q4
$2.27M Sell
12,431
-6,761
-35% -$944K ﹤0.01% 2711
2025
Q3
$2.33M Buy
19,192
+11,849
+161% +$1.33M ﹤0.01% 2733
2025
Q2
$767K Sell
7,343
-135
-2% -$14.3K ﹤0.01% 2929
2025
Q1
$872K Buy
+7,478
New +$852K ﹤0.01% 2907

Other funds holding AXSM

Dimensional Fund Advisors's AXSM Position: Q3 2026 in Review

Dimensional Fund Advisors reduced its Axsome Therapeutics (AXSM) stake by 18% in Q3 2026, selling an estimated $886K and leaving 18,595 shares worth $3.43M. The position accounts for ﹤0.01% of the portfolio, ranked #2594.

Dimensional Fund Advisors first reported a position in AXSM in Q1 2025 and has held it in 7 quarters since. The position peaked at $5.55M in Q2 2026. 466 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Dimensional Fund Advisors held 18,595 shares of Axsome Therapeutics worth $3.43M as of Q3 2026.
  • Dimensional Fund Advisors sold 4,075 Axsome Therapeutics shares in Q3 2026, an estimated $886K.
  • Axsome Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #2594 holding.
  • Dimensional Fund Advisors first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Dimensional Fund Advisors's Axsome Therapeutics position peaked at $5.55M in Q2 2026.
  • 466 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.